Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Cortex Pharmaceuticals |
---|---|
Information provided by: | Cortex Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00040443 |
Glutamate is fundamentally involved in learning and memory. Memory loss associated with mild cognitive impairment may be due to loss of glutamate receptors in the aging brain. There is evidence CX516 enhances brain activity by specifically targeting remaining glutamate receptors in the affected portions of the brain. This study will test the safety and efficacy of CX516 in the symptomatic treatment of participants with mild cognitive impairment.
Condition | Intervention | Phase |
---|---|---|
Mild Cognitive Impairment |
Drug: CX516 (Ampalex®) |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Efficacy And Safety Of CX516 (900 Mg t.i.d.) In Elderly Participants With Mild Cognitive Impairment. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group 4-Week Study. |
Ages Eligible for Study: | 55 Years to 85 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria
Exclusion criteria
United States, Arizona | |
Pivotal Research Centers | |
Peoria, Arizona, United States, 85381 | |
United States, California | |
University of California at Los Angeles | |
Los Angeles, California, United States, 90095 | |
University of California Irvine | |
Irvine, California, United States, 92697 | |
University of California, San Diego | |
San Diego, California, United States, 92093 | |
United States, Connecticut | |
Yale University School of Medicine | |
New Haven, Connecticut, United States, 06510 | |
United States, Florida | |
Sun Coast Gerontology Center, University of South Florida | |
Tampa, Florida, United States, 33617 | |
United States, Iowa | |
Mercy Mayo Clinic | |
Des Moines, Iowa, United States, 50314 | |
United States, Pennsylvania | |
University of Pittsburgh | |
Pittsburgh, Pennsylvania, United States, 15213 |
Study ID Numbers: | CORX-CX516-012.1 |
Study First Received: | June 26, 2002 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00040443 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Mild Cognitive Impairment Memory Loss Alzheimer's Disease |
Brain Aging Ampalex® CX516 |
Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Alzheimer Disease Dementia |
Cognition Disorders Amnesia Delirium |
Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Cognition Disorders |